RE: science continue15 Mar 2020 13:49
London, UK ., 10 March 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that it has posted a circular to shareholders providing details of a proposed capital reorganisation and authority to allot ordinary shares generally and for cash on a non-pre-emptive basis, which will require the approval of shareholders. A General Meeting has therefore been convened for 11.00 a.m. on 25 March 2020, to be held at the offices of Allenby Capital Limited, 5 St. Helen's Place, London, EC3A 6AB .